Form 4: Axsome Therapeutics COO Exercises Stock Options and Sells Shares for Substantial Gain

Axsome Therapeutics' Chief Operating Officer, Mark L. Jacobson, executed a pre-planned transaction, exercising 25,000 stock options and subsequently selling the acquired common shares for a significant profit.

Summary

• Mark L. Jacobson, Chief Operating Officer of Axsome Therapeutics, Inc. (AXSM), reported changes in his beneficial ownership of company securities.
• On June 9, 2025, Mr. Jacobson exercised 25,000 stock options at an exercise price of $8.02 per share.
• These options were set to expire within 12 months, having been granted on May 27, 2017, with an expiration date of May 27, 2026.
• Immediately following the option exercise, Mr. Jacobson sold 25,000 shares of common stock at a weighted average sale price of $110.44 per share.
• The sale prices for these shares ranged from $108.27 to $112.24.
• Both the option exercise and the subsequent sale were conducted pursuant to a pre-approved Rule 10b5-1 trading plan.
• Following these transactions, Mr. Jacobson's direct beneficial ownership of common stock stands at 5,783 shares, and he holds no derivative securities (stock options) from this specific grant.

Sentiment

Score: 5

Explanation: The transaction is a routine exercise of stock options and subsequent sale for liquidity by a company insider, executed under a 10b5-1 plan. While it represents a reduction in insider ownership, it's a common and often pre-scheduled event, not necessarily indicative of strong positive or negative company performance or outlook.

Positives

• The Chief Operating Officer realized a substantial profit from the exercise of stock options and subsequent sale of shares, indicating a significant increase in the company's stock value since the options were granted.
• The transaction was executed under a Rule 10b5-1 plan, which indicates a pre-scheduled and automated transaction, reducing concerns about opportunistic insider trading.

Negatives

• The sale of shares by a key executive, even if pre-planned, represents a reduction in insider ownership, which some investors might interpret as a neutral to slightly negative signal regarding future prospects, though it is a common practice for liquidity or diversification.

Future Outlook

This Form 4 filing pertains to an insider transaction and does not contain forward-looking statements or guidance regarding the company's future performance or outlook.

Management Comments

• "Represents an exercise of stock options prior to the 10-year expiration date of such options, which would occur within 12 months."
• "Such transaction was pursuant to a pre-approved 10b5-1 plan."
• "Represents the subsequent sale of the underlying shares of the aforementioned exercise of stock options."
• "Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $108.27 and $112.24."

Industry Context

Insider transactions, such as option exercises and subsequent share sales, are routine disclosures for publicly traded companies across all industries. This specific filing reflects an executive monetizing vested equity, a common practice, and does not inherently indicate broader industry trends or shifts.

Stakeholder Impact

• Shareholders: May observe a reduction in insider ownership, but the transaction's pre-planned nature (10b5-1) mitigates concerns about opportunistic selling. The significant profit realized by the COO could be viewed positively as it reflects the company's stock appreciation.

Key Dates

Recommendation

Keywords

Axsome Therapeutics, AXSM, Form 4, Insider Trading, Stock Options, Share Sale, Mark L. Jacobson, 10b5-1 Plan, Beneficial Ownership, Executive Compensation